🤍 Everyone you meet is fighting a battle you know nothing about. Be kind. Always. 🤍
🤍 Everyone you meet is fighting a battle you know nothing about. Be kind. Always. 🤍
The life sciences industry is facing a myriad of issues from a lack of investor accessibility to realignments across emerging to large organizations; which are adjusting everything from quantity of compounds in the pipeline to number of employees. Like many of you, I believe we've only seen the tip of the iceberg in terms of the lasting impact to the Inflation Reduction Act, so it's hard to gauge how many of these "right sizing" activities are appropriate and how many have been fear-based. Phoenix BioPharma Group was founded to be an organization focused on people first and as such I thought it made sense to show professionals in the #lifesciencesindustry that there are ways to #cutcostsNOTpeople. I will evaluate areas I think will bring the best ROI for the effort - operational excellence, inclusive of improved technology and people operations...
MLR Operations vs Marketing Operations vs. Content Operations so many terms for the same thing. Or is it really? In this article we define what Content Operations means and how it is shifting the industry and creating unprecedented opportunity.
It is the second week of 2024 and the life sciences industry is still in the middle of the same mid-life crisis of epic proportions that started at the end of 2022. We're in this weird phase of trying to catch up with technological advancements, and impending regulations combined with a lack of investors ponying up the dollars necessary to innovate. It feels like Groundhog Day with the continuous loop of organizations "right-sizing" for whatever the financial situation the company is facing, with a 57% increase in layoffs year over year from 2022 to 2023...
Click the image to continue reading.
The team at Phoenix BioPharma Group, LLC wrapped a project last month for an emerging pharma client and collaborated across 5 vendor teams to support the build out of this client's MLR process, DAM, and relevant technology. It was one of the most streamlined projects of my career (on either side - client or vendor) because we set ego aside and just did the things we needed to do. It was awe-inspiring!
Click the image to continue reading.
Our first large biotech project was with a partner we found to be very patient-centric and team focused. I feel incredibly lucky that their corporate values aligned so closely with our personal values. It was a genuine pleasure to work with these people who are so focused on creating cutting edge treatments to help pediatric patients live better and longer lives. As a result of this project and several other potential projects, I’ve found myself in more meetings than I ever would have imagined, with so many different people. There have been some very successful collaborations, and some not-so-successful ones. Here are the top five lessons learned so far.
Click the image to continue reading.
Congress' Promising Pathways Act and Biden's Inflation Reduction Act promise to do? One promises innovation and the other lower costs.🙄 In all my years of working Operations in the industry I have never seen these two concepts successfully occur simultaneously for any extended period.
Click the image to continue reading.
The ways AI can be used are evolving constantly and we've begun to utilize it to improve drug discovery, manufacturing, and personalize treatments for patients. It is also being used to speed up and simplify business processes across internal departments.
Click the image to continue reading.
How does OPDP's first letter of 2023 effect your MLR committee? More than you know, let's slap some orange lipstick on a pig and find out!
Click the image to continue reading.
With the consistent layoffs and lack of investor money available to the industry, the outlook is uncertain at best and a recession at worst. Learn practical and easy ways to assist your organization in launching a new product.
Click the image to continue reading.
According to a report by PhRMA, pharma companies spent an estimated $1.2 billion on speaker programs in 2022. This represents the second year in a row with a double digit decrease. The decline is likely due to a number of factors, including increased scrutiny of speaker programs by regulators.
Click the image to continue reading.
You’re trying to figure out how to make the remaining 5 months of the year productive, but your team’s been downsized to next to nothing. The amount of work hasn’t changed, just the number of hands to do it. That’s when you have to turn to a strategic consultant to support your success.
Click the image to continue reading.
What's a team to do in an industry where the landscape is constantly evolving and the day-to-day responsibilities just to "keep the lights on" can make it difficult for companies to keep up with the latest trends and best practices until it's a guidance? Whether it's a priority issue or a people resource issue, this is where life sciences consultants come in.
Click the image to continue reading.
An exceptionally important process that needs to be set up, well in advance of product launch, is promotional review committee or PRC (it is also known as Medical, Legal, Regulatory or MLR and Material Review Committee or MRC).
Click the image to continue reading.
When I was younger, the word pharma used to give me a bad taste in my mouth. The opioid crisis hit my family hard, like so many others, and images of wealthy pharma CEOs bribing doctors to overprescribe medication had strongly tainted my view of the industry. I took a great deal of misplaced pride in almost never needing any prescriptions.
Click the image to continue reading.
Phoenix BioPharma Group, LLC
430 Franklin Village Dr #179 Franklin, MA 02038
🫶🏼 Be Kind. Always. 🫶🏼
© 2024 Phoenix BioPharma Group - All Rights Reserved.
Welcome! Check out our new cost cutting services so you can reduce your spend and keep your team.